arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Scilex Holding Co

SCLX
$1.67 ▼ -0.16 (-8.74%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
6 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
73
Health
Good
Bullish
auto_awesome

Analytical Summary

Scilex Holding Co shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —
Dividend Yield —
Revenue Growth -46.5% ↘
Op. Margin None
ROIC 166.5% ↗
FCF / Share None
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

6-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$30.25M
↓ -46.5% —
Net Income Profit after all expenses
$-374.05M
↓ -413.8% —
Operating Margin Operating profit as % of sales
-147.4%
↑ +34.7% —
FCF / Share Free cash flow per share
$0.15
↑ +192.7% —
Long-Term Debt Long-term obligations
$0.00
↓ -100.0% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
66
Returns ↑
100
Cash Quality
22

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 6 years · 26 quarters